These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8093363)

  • 81. Lymphocytes' intrinsic lymphoproliferative capacity in patients with AIDS treated with zidovudine.
    Gerding MN; Schuurman HJ; Bast BJ; Borleffs JC
    AIDS; 1989 Oct; 3(10):671-3. PubMed ID: 2574585
    [No Abstract]   [Full Text] [Related]  

  • 82. Prolonged antiviral activity of D-penicillamine in human immunodeficiency virus-infected homosexual men.
    Scheib RG; Parenti DM; Simon GL; Courtless JW; Schulof RS; Sarin PS; Chandra P
    Am J Med; 1987 Sep; 83(3):608. PubMed ID: 3661606
    [No Abstract]   [Full Text] [Related]  

  • 83. A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection.
    Kaplan CS; Petersen EA; Yocum D; Hersh EM
    Life Sci; 1989; 45(22):iii-ix. PubMed ID: 2557513
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells.
    Zhu Z; Ho HT; Hitchcock MJ; Sommadossi JP
    Biochem Pharmacol; 1990 May; 39(9):R15-9. PubMed ID: 2159302
    [No Abstract]   [Full Text] [Related]  

  • 85. Surrogate markers in AIDS: where are we? Where are we going?
    Lagakos SW; Hoth DF
    Ann Intern Med; 1992 Apr; 116(7):599-601. PubMed ID: 1347443
    [No Abstract]   [Full Text] [Related]  

  • 86. Development of immunosupportive drugs for patients with AIDS/ARC.
    Gottlieb AA; Garry RF
    Clin Immunol Immunopathol; 1988 Jun; 47(3):241-4. PubMed ID: 3370858
    [No Abstract]   [Full Text] [Related]  

  • 87. Pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in the neonatal macaque (Macaca nemestrina).
    Keller RD; Nosbisch C; Unadkat JD
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2829-31. PubMed ID: 8593033
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Targets and strategies for the antiviral chemotherapy of AIDS.
    De Clercq E
    Trends Pharmacol Sci; 1990 May; 11(5):198-205. PubMed ID: 2188403
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus.
    August EM; Marongiu ME; Lin TS; Prusoff WH
    Biochem Pharmacol; 1988 Dec; 37(23):4419-22. PubMed ID: 2849444
    [No Abstract]   [Full Text] [Related]  

  • 90. Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides.
    Yarchoan R; Broder S
    Pharmacol Ther; 1989; 40(3):329-48. PubMed ID: 2646649
    [No Abstract]   [Full Text] [Related]  

  • 91. Reverse transcriptase activity (RTA) in lymphocyte cultures of AIDS patients treated with HPA-23.
    Buimovici-Klein E; Ong KR; Lange M; Englard A; McKinley GF; Reddy M; Grieco MH; Cooper LZ
    AIDS Res; 1986; 2(4):279-83. PubMed ID: 2434115
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Multistep Continuous Flow Synthesis of Stavudine.
    Sagandira CR; Akwi FM; Sagandira MB; Watts P
    J Org Chem; 2021 Oct; 86(20):13934-13942. PubMed ID: 34060836
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity.
    Feder AF; Harper KN; Brumme CJ; Pennings PS
    Elife; 2021 Sep; 10():. PubMed ID: 34473060
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication.
    Reynard O; Nguyen XN; Alazard-Dany N; Barateau V; Cimarelli A; Volchkov VE
    Viruses; 2015 Dec; 7(12):6233-40. PubMed ID: 26633464
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Low dose versus high dose stavudine for treating people with HIV infection.
    Magula N; Dedicoat M
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007497. PubMed ID: 25627012
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A review of the toxicity of HIV medications.
    Margolis AM; Heverling H; Pham PA; Stolbach A
    J Med Toxicol; 2014 Mar; 10(1):26-39. PubMed ID: 23963694
    [TBL] [Abstract][Full Text] [Related]  

  • 97. HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain.
    Denk F; Huang W; Sidders B; Bithell A; Crow M; Grist J; Sharma S; Ziemek D; Rice ASC; Buckley NJ; McMahon SB
    Pain; 2013 Sep; 154(9):1668-1679. PubMed ID: 23693161
    [TBL] [Abstract][Full Text] [Related]  

  • 98. HIV-associated sensory neuropathy: risk factors and genetics.
    Kamerman PR; Wadley AL; Cherry CL
    Curr Pain Headache Rep; 2012 Jun; 16(3):226-36. PubMed ID: 22367397
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy.
    Pujades-Rodríguez M; Dantony E; Pinoges L; Ecochard R; Etard JF; Carrillo-Casas E; Szumilin E;
    PLoS One; 2011; 6(11):e28112. PubMed ID: 22132226
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
    Vanprapar N; Cressey TR; Chokephaibulkit K; Muresan P; Plipat N; Sirisanthana V; Prasitsuebsai W; Hongsiriwan S; Chotpitayasunondh T; Eksaengsri A; Toye M; Smith ME; McIntosh K; Capparelli E; Yogev R;
    Pediatr Infect Dis J; 2010 Oct; 29(10):940-4. PubMed ID: 20453709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.